AXSOME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.71 USD | +0.27% |
|
+5.61% | -9.90% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,805 | 3,042 | 1,424 | 3,349 | 3,766 | 3,406 | - | - |
| Enterprise Value (EV) 1 | 3,605 | 2,907 | 1,387 | 3,243 | 3,558 | 3,321 | 3,253 | 2,779 |
| P/E ratio | -51.4 x | -29.4 x | -10.9 x | -16.8 x | -15.1 x | -18.7 x | 72.8 x | 10.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 66.9 x | 13.9 x | 9.05 x | 4.97 x | 3.12 x |
| EV / Revenue | - | - | - | 64.8 x | 13.1 x | 8.82 x | 4.75 x | 2.54 x |
| EV / EBITDA | - | -29.3 x | -11.1 x | -18.5 x | -15.8 x | -22.1 x | 34.3 x | 7.06 x |
| EV / FCF | -77.7 x | -37 x | -12.8 x | -27.7 x | -24.4 x | -21.5 x | -236 x | 13 x |
| FCF Yield | -1.29% | -2.7% | -7.83% | -3.61% | -4.09% | -4.66% | -0.42% | 7.71% |
| Price to Book | 21.4 x | 26.8 x | 90.9 x | 30.6 x | 19.7 x | 56.2 x | 17 x | 4.95 x |
| Nbr of stocks (in thousands) | 36,809 | 37,344 | 37,692 | 43,426 | 47,320 | 47,493 | - | - |
| Reference price 2 | 103.4 | 81.47 | 37.78 | 77.13 | 79.59 | 71.71 | 71.71 | 71.71 |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 2/27/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 50.04 | 270.6 | 376.4 | 685.4 | 1,093 |
| EBITDA 1 | - | -99.12 | -124.6 | -175.4 | -225 | -150.5 | 94.92 | 393.6 |
| EBIT 1 | -67.25 | -99.14 | -124.7 | -179.8 | -231.8 | -165.7 | 76.47 | 407.8 |
| Operating Margin | - | - | - | -359.33% | -85.67% | -44.03% | 11.16% | 37.31% |
| Earnings before Tax (EBT) 1 | -68.48 | -101.7 | -130.4 | -187.1 | -238.3 | -173.4 | 101.2 | 460.7 |
| Net income 1 | -68.35 | -102.9 | -130.4 | -187.1 | -239.2 | -183.3 | 53.8 | 367.9 |
| Net margin | - | - | - | -373.99% | -88.41% | -48.7% | 7.85% | 33.66% |
| EPS 2 | -2.010 | -2.770 | -3.470 | -4.600 | -5.270 | -3.831 | 0.9853 | 7.030 |
| Free Cash Flow 1 | -46.39 | -78.5 | -108.5 | -117.2 | -145.7 | -154.6 | -13.76 | 214.1 |
| FCF margin | - | - | - | -234.25% | -53.83% | -41.07% | -2.01% | 19.59% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 54.41% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 58.21% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 2/27/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 8.82 | 16.85 | 24.37 | 94.58 | 46.7 | 57.79 | 71.53 | 73.04 | 87.63 | 101.1 | 117.9 | 110.4 |
| EBITDA 1 | - | - | - | - | -40.77 | -58.22 | - | - | - | -96.53 | -60.11 | -55.23 | -48.68 | -43.5 | - |
| EBIT 1 | -33.41 | -32.61 | -38.29 | -39.18 | -42.45 | -59.92 | -6.374 | -65.06 | -62.12 | -98.27 | -55.37 | -46.02 | -36.56 | -24.07 | -28 |
| Operating Margin | - | - | - | -444.24% | -252.02% | -245.85% | -6.74% | -139.31% | -107.49% | -137.39% | -75.81% | -52.52% | -36.17% | -20.42% | -25.37% |
| Earnings before Tax (EBT) 1 | -34.88 | -33.98 | -39.63 | -41.44 | -44.82 | -61.24 | -8.638 | -67.79 | -62.88 | -98.98 | -56.59 | -45.83 | -35.61 | -22.28 | -24.7 |
| Net income 1 | -34.88 | -33.98 | -39.63 | -41.44 | -44.82 | -61.24 | -11.22 | -67.17 | -62.2 | -98.65 | -58.04 | -47.55 | -37.9 | -26.29 | -24.7 |
| Net margin | - | - | - | -469.84% | -266.08% | -251.28% | -11.86% | -143.83% | -107.62% | -137.91% | -79.46% | -54.27% | -37.51% | -22.31% | -22.37% |
| EPS 2 | -0.9300 | -0.9000 | -1.030 | -1.060 | -1.070 | -1.410 | -0.2600 | -1.540 | -1.320 | -2.080 | -1.219 | -1.014 | -0.8003 | -0.5441 | -0.6600 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/1/22 | 5/2/22 | 8/9/22 | 11/7/22 | 2/27/23 | 5/9/23 | 8/7/23 | 11/6/23 | 2/20/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 200 | 136 | 37.4 | 107 | 208 | 84.9 | 153 | 627 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -46.4 | -78.5 | -109 | -117 | -146 | -155 | -13.8 | 214 |
| ROE (net income / shareholders' equity) | - | -69.5% | -202% | -299% | -159% | -139% | 47.3% | 87.2% |
| ROA (Net income/ Total Assets) | -57.9% | - | -95.2% | -89.3% | - | - | - | - |
| Assets 1 | 118 | - | 137 | 209.6 | - | - | - | - |
| Book Value Per Share 2 | 4.840 | 3.040 | 0.4200 | 2.520 | 4.030 | 1.280 | 4.230 | 14.50 |
| Cash Flow per Share 2 | - | -2.110 | -2.880 | -2.870 | -3.190 | -3.580 | - | - |
| Capex 1 | 0.02 | 0.05 | 0.31 | 0.7 | 0.58 | 1.22 | 1.57 | 2.05 |
| Capex / Sales | - | - | - | 1.4% | 0.22% | 0.33% | 0.23% | 0.19% |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 2/27/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
71.71
USD
Average target price
121.1
USD
Spread / Average Target
+68.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.90% | 3.4B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- AXSM Stock
- Financials Axsome Therapeutics, Inc.
